+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID05978284

Phase 12 Study of ZG006 Given by IV to Treat Adults With Small Cell Lung Cancer or Neuroendocrine Carcinoma Who Have No Standard Treatment Options

Led by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Updated on 2026-01-05

54

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating ZG006 in a Phase 12 clinical trial for adults aged 18 to 75 with small cell lung cancer or neuroendocrine carcinoma who either have no standard treatment options or cannot tolerate standard treatments. This multi-center, open-label study aims to understand the safety, tolerability, pharmacokinetics, and effects of ZG006 in this patient population. Participants will receive ZG006 through intravenous infusion. The study includes a dose-escalation phase using accelerated titration for lower doses and a conventional dose escalation method for higher doses to find the maximum tolerated dose and recommended dose for Phase 2. After dose exploration, participants will receive the identified optimal dose during the dose expansion phase. During the trial, participants will be closely monitored for dose-limiting toxicities within 28 days after the first dose, as well as adverse events, laboratory results, and changes in ECGs for up to two years. Researchers will also assess treatment response, including tumor control and drug concentration levels in the blood. The total study duration may last up to two years, including safety and efficacy follow-up.

CONDITIONS

Brief Title

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Research Team

H

Hewen Yin

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here